High throughput genetic methods and the development of novel technologies such as RNA interference (RNAi) are rapidly transforming both basic biological science and biomedicine requiring restructuring of conventional research units. Because of the highly specialized and capital-intensive nature of genomics instrumentation and reagent sets these should be developed as core infrastructures providing services to researchers nationally. Integration and focusing of local services was initiated within this network in BF in 2007 and led to national recognition on the Roadmap of National Research Insfrastructures (2008).
In addition to ongoing support for genetics, genomics, and gene expression and regulation, recent investments into systems biology and high-throughput technologies have already provided critical support for world-leading scientific research. Cost-effective access to reagents and libraries enabling knockdowns or overexpression as well as high-throughput facilities is provided nationwide as a collaborative effort of Helsinki units. High-content screening services are customized to local research strengths and integrated with imaging and translational technologies. The genome-wide BF network will continue as an expert body to coordinate training efforts, to evaluate the services, to facilitate the use of these services in biocenters throughout Finland, and to integrate these activities internationally.
Services include eg. resequencing; de novo sequencing; metagenomics; targeted sequencing; SNP genotyping (GWAS); targeted SNP genotyping; copy number variation.
Faculty of Medicine and Health Technology (Tampere University)
BMT Cancer Genomics
Services include eg. immunoprecipitations; DNA methylation analysis; RNA-seq; gene expression microarrays; Nanostrings, QuantStudioTM 12K Flex system
Services include eg. genome-scale reagents; ORF cloning; siRNA, shRNA, ORF, miRNA screens; high-content analysis
University of Helsinki
Outi Monni (HiLIFE, Biomedicum Functional Genomics Unit (FuGU)); Petri Auvinen (BI, DNA Sequencing and Genomics Laboratory (BI-DGEN)); Saara Ollila (HiLIFE, Genome-biology Unit (GBU)); Riitta Lahesmaa & Minna Kyläniemi (BioCity Turku, Finnish Functional Genomics Centre (FFGC)); Kati Donner (FIMM Technology Center; DNA Sequencing and Genotyping Laboratory; High-throughput Screening Facility); Heini Kallio (Faculty of Medicine and Health Technology (Tampere University), BMT Cancer Genomics)